New model aims to spot Alzheimer's risk years before symptoms worsen

NCT ID NCT07516119

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study is testing a new model that combines genetic data, blood tests, and digital monitoring (like sleep and activity trackers) to predict early memory decline in adults aged 55 and older who carry the ApoE4 gene variant. Researchers will follow 100 participants for 24 months to see if the model can identify who develops signs of Alzheimer's disease. The study does not test any treatment, but aims to improve early detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to better tools for early detection of Alzheimer's-related memory decline, allowing earlier intervention.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. The model may not be accurate enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction Genetic Risk Score

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Foster Carr MD

    RECRUITING

    San Diego, California, 92101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.